As Biotechnology companies, Allogene Therapeutics Inc. (NASDAQ:ALLO) and Infinity Pharmaceuticals Inc. (NASDAQ:INFI) are our subject to contrast. And more specifically their risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation.

Earnings and Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allogene Therapeutics Inc.	N/A	0.00	211.50M	0.00	0.00
Infinity Pharmaceuticals Inc.	22.15M	4.81	11.25M	1.25	1.28

In table 1 we can see Allogene Therapeutics Inc. and Infinity Pharmaceuticals Inc.’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 represents Allogene Therapeutics Inc. (NASDAQ:ALLO) and Infinity Pharmaceuticals Inc. (NASDAQ:INFI)?s return on assets, net margins and return on equity.

	Net Margins	Return on Equity	Return on Assets
Allogene Therapeutics Inc.	0.00%	0%	0%
Infinity Pharmaceuticals Inc.	-50.79%	-20.8%	-18.2%

Liquidity

The current Quick Ratio of Allogene Therapeutics Inc. is 1.6 while its Current Ratio is 1.6. Meanwhile, Infinity Pharmaceuticals Inc. has a Current Ratio of 10.7 while its Quick Ratio is 10.7. Infinity Pharmaceuticals Inc. is better positioned to pay off its short-term and long-term debts than Allogene Therapeutics Inc.

Analyst Recommendations

The table given features the ratings and recommendations for Allogene Therapeutics Inc. and Infinity Pharmaceuticals Inc.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Allogene Therapeutics Inc.	0	0	1	3.00
Infinity Pharmaceuticals Inc.	1	1	1	2.33

The upside potential is 55.95% for Allogene Therapeutics Inc. with average target price of $40. Infinity Pharmaceuticals Inc. on the other hand boasts of a $3 average target price and a 60.43% potential upside. The data from earlier shows that analysts opinion suggest that Infinity Pharmaceuticals Inc. seems more appealing than Allogene Therapeutics Inc.

Institutional & Insider Ownership

Roughly 52.3% of Allogene Therapeutics Inc. shares are held by institutional investors while 54.9% of Infinity Pharmaceuticals Inc. are owned by institutional investors. Insiders held roughly 21.2% of Allogene Therapeutics Inc.’s shares. Comparatively, insiders own roughly 1.1% of Infinity Pharmaceuticals Inc.?s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Allogene Therapeutics Inc.	0.66%	5.31%	4.72%	0%	0%	18.6%
Infinity Pharmaceuticals Inc.	-3.03%	32.23%	16.79%	-21.57%	-16.67%	35.59%

For the past year Allogene Therapeutics Inc. has weaker performance than Infinity Pharmaceuticals Inc.

Summary

Infinity Pharmaceuticals Inc. beats Allogene Therapeutics Inc. on 8 of the 12 factors.

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the research, development, and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, a CAR T cell product candidate targeting CD19, which is in clinical trials in patients with R/R B-cell precursor acute lymphoblastic leukemia; ALLO-501, an allogeneic anti-CD19 CAR T cell product candidate for the treatment of patients with R/R non-Hodgkin lymphoma; ALLO-715, an allogeneic CAR T cell product candidate for the treatment of patients with R/R multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody for use as a lymphodepleting agent. It is also developing ALLO-819, an anti-Flt3 product candidate for the treatment of acute myeloid leukemia; CD70 for the treatment of renal cell cancer; and DLL3 for the treatment of small cell lung cancer. The company was founded in 2017 and is headquartered in South San Francisco, California.

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for patients with difficult-to-treat diseases in the United States. Its lead product candidate includes IPI-549 an orally administered immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma) is in Phase 1 clinical study. The company has a license agreement with Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib, a selective inhibitor of the PI3K delta and gamma isoforms, including DUO study that is in randomized Phase III clinical study for patients with relapsed/refractory chronic lymphocytic leukemia and products containing duvelisib; Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; and Takeda Pharmaceutical Company Limited to develop and commercialize duvelisib. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.